NCT03187886

Brief Summary

INTRODUCTION: Cerebral amyloid angiopathy-related inflammation (CAA-ri) is a very rare manifestation of cerebral amyloid angiopathy, characterized by acute/subacute neurological deterioration and T2/FLAIR corticosubcortical or deep white matter hyperintensity. With the advent of new diagnostic criteria, there are more and more case reports and series reported; nevertheless, MRI findings and follow-up data need to be thoroughly described. OBJECTIVES: Our aim in this multicentrical and retrospective study was to describe the clinical and radiological features of patients with CAA-ri and assess long-term prognosis. METHODS: We reviewed the characteristics of 28 patients with CAA-ri including clinical data, systematic MRI analysis, cerebrospinal fluid results (including Alzheimer's disease biomarkers) and APOE genotype. HYPOTHESIS: We aimed at describing the clinical and radiological characteristics of a cohort of patients with CAA-ri.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
28

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jan 2017

Shorter than P25 for all trials

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2017

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

June 12, 2017

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 12, 2017

Completed
3 days until next milestone

First Posted

Study publicly available on registry

June 15, 2017

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2017

Completed
Last Updated

December 5, 2017

Status Verified

June 1, 2017

Enrollment Period

5 months

First QC Date

June 12, 2017

Last Update Submit

December 1, 2017

Conditions

Cerebral Amyloid Angiopathy Related Inflammation

Keywords

Cerebral amyloid angiopathyCAA-RIMRIIntracerebral hemorrhage

Outcome Measures

Primary Outcomes (1)

  • MRI results

    MRI results and Follow-up

    1 day

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

cerebral amyloid angiopathy related inflammation

You may qualify if:

  • Presence of possible or probable amyloid angiopathy according to the most recent diagnostic criteria (Auriel et al., 2016) Or
  • Presence of amyloid angiopathy with perivascular inflammatory infiltrate not meeting the criteria for inflammatory amyloid angiopathy cited above.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Cerebral Amyloid AngiopathyCerebral Hemorrhage

Condition Hierarchy (Ancestors)

Cerebral Arterial DiseasesIntracranial Arterial DiseasesCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular DiseasesAmyloidosisProteostasis DeficienciesMetabolic DiseasesNutritional and Metabolic DiseasesIntracranial HemorrhagesHemorrhagePathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Xavier AYRIGNAC, MD

    University Hospital, Montpellier

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 12, 2017

First Posted

June 15, 2017

Study Start

January 1, 2017

Primary Completion

June 12, 2017

Study Completion

July 31, 2017

Last Updated

December 5, 2017

Record last verified: 2017-06